

OncoTherapy Science, Inc.

March 1, 2018

Announcement of research collaboration between OTS's subsidiary company and
Japanese Foundation for Cancer Research (JFCR)

OncoTherapy Science, Inc. (OTS) announces that one of our subsidiary companies, Cancer Precision Medicine, Inc. (CPM) has agreed on a research collaboration with JFCR about liquid biopsy study for the detection of mutated circulating tumor DNA (ctDNA).

For the diagnosis of solid cancers (such as lung cancer, colorectal cancer, breast cancer), this collaborative research will improve liquid biopsy technology in the detection of specific gene mutations and will also develop new technologies (including new gene panels), aiming to clinical applications of liquid biopsy. Using cancer patient's liquid specimens like blood and urine, CPM and JFCR will collaborate to examine the potential of liquid biopsy at various levels, such as evaluation of JFCR's own liquid biopsy technology and applications in cancer screening, selection of molecular targeted therapies, and monitoring of tumor recurrence.

CPM provides next-generation sequencing analysis, prediction of neoantigen, liquid biopsy, TCR/BCR repertoire analysis, and immune monitoring, in order to accelerate the cancer precision medicine in Japan. In addition, CPM conducts both research and development for the new type of personalized immunotherapy solutions, such as neoantigen-targeting dendritic cell therapy and TCR-engineered adoptive T cell therapy.